SCHEMBL3827601

SCHEMBL3827601

CCCC=CCC(CCCCCCCCCCCCCCCC)(OC(CC=CCCC)(CCCCCCCCCCCCCCCC)C(O)CO)C(O)CO

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.36
CYP2D6 P10635 3/20 0.36
MAPK1 P28482 3/20 0.36
TP53 P04637 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
DGKA P23743 1/20 0.36
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
GMNN O75496 2/20 0.35
LMNA P02545 2/20 0.35
GLA P06280 2/20 0.35
POLB P06746 2/20 0.35
THRB P10828 2/20 0.35
CETP P11597 2/20 0.35
CXCR5 P32302 2/20 0.35
CCR6 P51684 2/20 0.35
BLM P54132 2/20 0.35
UBE2N P61088 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10357997 0.82 USP2 (0.40) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL11150089 0.82 USP2 (0.40) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL4394710 0.81 USP2 (0.39) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL3807431 0.81 USP2 (0.37) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL3802891 0.78 DGKA (0.43) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL6150150 0.77 MAPT (0.49) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL3257927 0.77 ALDH1A1 (0.47) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL4199170 0.77 ALDH1A1 (0.47) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL5190830 0.75 CNR2 (0.42) MAPTCYP2D6MAPK1TP53CYP1A2
SCHEMBL8842885 0.75 LMNA (0.41) MAPTCYP2D6TP53CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341543-A4 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS VASCULAR BIOGENICS LTD (IL) 2009-09-02 EP disclosed
EP-1626728-A4 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD (IL) 2009-09-02 EP disclosed
EP-1626728-A2 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS Vascular Biogenics Ltd. (IL) 2006-02-22 EP disclosed
WO-2004106486-A2 OXIDIZED LIPIDS AND USES THEREOF IN THE TREATMENT OF INFLAMMATORY DISEASES AND DISORDERS VASCULAR BIOGENICS LTD. (IL) 2004-12-09 WO disclosed
EP-1341543-A2 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS Vascular Biogenics Ltd. (IL) 2003-09-10 EP disclosed
WO-2002041827-A9 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS VASCULAR BIOGENICS LTD (IL) 2003-05-30 WO disclosed
WO-2002041827-A2 METHODS EMPLOYING AND COMPOSITIONS CONTAINING DEFINED OXIDIZED PHOSPHOLIPIDS FOR PREVENTION AND TREATMENT OF ATHEROSCLEROSIS VASCULAR BIOGENICS LTD. (IL) 2002-05-30 WO disclosed